Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

  • days left to enroll
  • participants needed
  • sponsor
    Damascus University
Updated on 3 February 2021


Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte quality is determined based on its nuclear maturation and the presence of specific cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS) protocols in order to prevent premature luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type of GnRH analogues used during COS could affect the oocyte morphology in polycystic ovary syndrome (PCOS) patients. The aim of this prospective, non-randomised, open-label, clinical trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on oocyte morphology in PCOS patients during IVF/ICSI.

Condition OVARIAN CYST, Intracytoplasmic sperm injection, Female Genital Diseases, Infertility, In Vitro Fertilization, Polycystic Ovary Syndrome, Gynecological Infections, Ovarian Cysts, Polycystic Ovarian Syndrome, pcos, polycystic ovary disease, icsi, sterility, unable to conceive
Treatment Triptorelin acetate, Cetrorelix, Human Chorionic Gonadotropin (hCG), recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Clinical Study IdentifierNCT04727684
SponsorDamascus University
Last Modified on3 February 2021


Yes No Not Sure

Inclusion Criteria

PCOS women undergoing IVF/ICSI
Age: 18-39 years
Both ovaries present

Exclusion Criteria

Age 40 years
History of three or more previous IVF failures
Patients with hormonal disorders like hyperprolactinemia, thyroid disorders
Patients who previously undergo Unilateral Oophorectomy
Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases
Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids, Hydrosalpinx, Adenomyosis, autoimmune diseases
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note